| 吉非替尼治疗晚期非小细胞肺癌的临床观察 |
| |
| 引用本文： | 孙小峰,陈嘉. 吉非替尼治疗晚期非小细胞肺癌的临床观察[J]. 中国医药导刊, 2011, 13(10): 1749-1750 |
| |
| 作者姓名： | 孙小峰 陈嘉 |
| |
| 作者单位： | 江苏省肿瘤医院内科,南京,210009 |
| |
| 摘 要： | 目的:临床研究显示吉非替尼(gefitinib),用于治疗既往接受过化学治疗的局部晚期或转移性非小细胞肺癌(NSCLC)疗效显著,毒副反应轻。本研究观察吉非替尼治疗既住接受过化学治疗的晚期NSCLC的临床疗效和毒副反应。方法:吉非替尼250mg(1片),1日1次,口服,空腹或与食物同服。结果:全组50例,均可评价疗效,总有效率为22.0%(11/50),其中完全缓解(CR)2.0%(1/50),部分缓解(PR)20.0%(10/50),无变化(NC)50.0%(25/50),疾病控制率(CR+PR+NC)72.2%,中位无进展生存期14月。无治疗相关死亡,主要毒副反应为皮疹、腹泻。结论:吉非替尼治疗既往接受过化学治疗的晚期NSCLC疾病控制率较高、不良反应患者可耐受,是治疗晚期NSCLC有效安全的药物。
|
| 关 键 词： | 吉非替尼 非小细胞肺癌 |
Clinical Effect and Side Reactions of Advanced Non-Small-Cell Lung Cancer Treated with Gefitinib |
| |
| Sun Xiao-feng,Chen Jia. Clinical Effect and Side Reactions of Advanced Non-Small-Cell Lung Cancer Treated with Gefitinib[J]. Chinese Journal of Medicinal Guide, 2011, 13(10): 1749-1750 |
| |
| Authors: | Sun Xiao-feng Chen Jia |
| |
| Affiliation: | (Department of Internal Medicine Jiangsu Tumor hospital,Nanjing 210009,China) |
| |
| Abstract: | Objective:Clinical study showed that gefitinib is effective and safe in treatment of advanced non-small-cell lung cancer(NSCLC).The trial investigated the activity and toxicity of advanced non-small-cell lung cancer treated with gefitinib.Methods:50 patients with advanced NSCLC received gefitinib(gefitinib 250 mg,po qd).Curative and side effects were evaluated after 30 days.Results: The efficacy was 22.0%(11/50),CR 2.0%(1/16),PR 20.0%(10/50),NC50.0%(25/50),disease control rates(CR+PR+NC)was 72.2%.Median time of progression was 14 months.The acneiform rash and diarrhea were the main toxicities.Conclusion:Gefitnib has a high disease control rates with tolerable toxicities in patients with advanced NSCLC. |
| |
| Keywords: | Gefitnib Advanced non-small-cell lung cancer |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
